BioAtla (BCAB) Expected to Announce Quarterly Earnings on Tuesday

Posted by Geri Gentry on May 5th, 2026

BioAtla (NASDAQ:BCAB – Get Free Report) is projected to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($10.00) per share and revenue of $1.7190 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

BioAtla (NASDAQ:BCAB – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($8.00) EPS for the quarter, topping analysts’ consensus estimates of ($18.00) by $10.00. The company had revenue of $2.00 million during the quarter, compared to analysts’ expectations of $0.70 million.

BioAtla Price Performance

BioAtla stock traded down $0.31 during trading hours on Tuesday, reaching $4.40. The company had a trading volume of 47,329 shares, compared to its average volume of 47,954. BioAtla has a 12-month low of $3.92 and a 12-month high of $71.50. The firm has a market cap of $7.30 million, a price-to-earnings ratio of -0.09 and a beta of 0.81. The company has a 50-day moving average price of $7.15 and a 200 day moving average price of $21.55.

Institutional Investors Weigh In On BioAtla

Several hedge funds have recently added to or reduced their stakes in BCAB. Woodline Partners LP bought a new stake in BioAtla in the first quarter worth $26,000. ADAR1 Capital Management LLC bought a new stake in BioAtla in the fourth quarter worth $104,000. Susquehanna International Group LLP boosted its holdings in BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after acquiring an additional 177,760 shares in the last quarter. Jane Street Group LLC boosted its holdings in BioAtla by 55.4% in the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after acquiring an additional 123,597 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in BioAtla in the third quarter worth $235,000. 77.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BCAB. Rodman & Renshaw began coverage on BioAtla in a research note on Tuesday, January 13th. They issued a “buy” rating and a $200.00 price target for the company. Wall Street Zen upgraded shares of BioAtla to a “hold” rating in a report on Saturday, April 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAtla in a research report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $200.00.

View Our Latest Stock Analysis on BCAB

BioAtla Company Profile

(Get Free Report)

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.